Receptor (biochemistry)

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Retrieved on: 
Montag, Juni 10, 2024
Patient, Research, Therapy, SNMMI, MTIC, Cancer, Nuclear medicine, Receptor (biochemistry), Molecular imaging, Medical imaging

SNMMI is the premier educational, scientific, and research event in the radiopharma space.

Key Points: 
  • SNMMI is the premier educational, scientific, and research event in the radiopharma space.
  • Monopar’s poster highlights the potential promise of both the urokinase plasminogen activator receptor (uPAR) as a radiopharma cancer target for solid tumors as well as MNPR-101 as a targeting agent against uPAR.
  • Monopar recently initiated a first-in-human Phase 1 imaging and dosimetry clinical trial in advanced cancer patients with MNPR-101-Zr.
  • The study is led by internationally recognized radiopharmaceutical physician Prof. Rodney Hicks, founder of the Melbourne Theranostic Innovation Centre (MTIC).

InflaRx Hosts R&D Event Highlighting the Promise of INF904

Retrieved on: 
Mittwoch, Juni 5, 2024
I&I, Research, Patient, Nephrology, University of North Carolina, Safety, Hidradenitis suppurativa, UAS7, CSU, University, PRO, Receptor (biochemistry), Inflammation, Therapy, Medical school, Hematology, Calendar, HS, Biomarker, Quality of life, BID, Neurology, Pharmaceutical industry

Supplemental information related to today’s event, including presentations conducted by the KOLs and InflaRx management can be found in the accompanying slide deck here .

Key Points: 
  • Supplemental information related to today’s event, including presentations conducted by the KOLs and InflaRx management can be found in the accompanying slide deck here .
  • Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “InflaRx has been eager to provide additional details of its development plans for INF904 and to further showcase the tremendous promise of our approach to C5aR inhibition, initially in CSU and HS, and more broadly in I&I.
  • In the CSU group, patients in Study Arms 1 and 2 will be dosed with INF904 at 30 mg and 90 mg BID (twice daily), respectively.
  • Given the potential of INF904 to have a broad commercial footprint, InflaRx believes INF904 could address meaningful markets in immuno-dermatology and in immuno-inflammation, including in nephrology, neurology and hematology.

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

Retrieved on: 
Donnerstag, Mai 9, 2024
Receptor (biochemistry), Society, Cancer, Investment, Patent, Patient, MTIC, Neoplasm, Clinical trial, G&A

WILMETTE, Ill., May 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced first quarter 2024 financial results and summarized recent developments.

Key Points: 
  • Based on these advances, Monopar has made the strategic decision to focus its resources on the assets and capabilities it has been building up in the radiopharma space.
  • Results for the First Quarter Ended March 31, 2024, Compared to the First Quarter Ended March 31, 2023
    Cash, cash equivalents and short-term investments as of March 31, 2024, were $8.8 million.
  • R&D expenses for the first quarter of 2024 were $966,000 compared to $1,653,000 for the first quarter of 2023.
  • G&A expenses for the first quarter of 2024 were $757,000, compared to $872,000 for the first quarter of 2023.

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

Retrieved on: 
Dienstag, April 16, 2024
Receptor (biochemistry), Cancer, MD, Radionuclide, Patent, Patient, Therapy, Pharmaceutical industry

Monopar expects this provisional patent application to further strengthen its intellectual property around the MNPR-101 radiopharma program, under which the Company is aiming to develop therapies for numerous hard-to-treat advanced cancers that express uPAR.

Key Points: 
  • Monopar expects this provisional patent application to further strengthen its intellectual property around the MNPR-101 radiopharma program, under which the Company is aiming to develop therapies for numerous hard-to-treat advanced cancers that express uPAR.
  • Monopar recently announced the initiation of its Phase 1 dosimetry clinical trial for MNPR-101-Zr in patients with advanced cancers.
  • “Filing of this provisional patent application is aimed at further protecting our novel MNPR-101 radiopharmaceutical program,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • “This patent filing along with our earlier patent filings helps to create a broad portfolio of intellectual property around this program and potential future programs.”

Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases

Retrieved on: 
Montag, April 15, 2024
Receptor (biochemistry), Podocyte, Kidney disease, Safety, Kidney, Pharmacokinetics, Fibrinolysis, Trial of the century, Reduction, Dialysis, Monoclonal antibody, Pharmaceutical industry

CAMBRIDGE, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Walden Biosciences, Inc. (Walden), a private, venture-backed clinical development stage company focused on disease-modifying, transformative therapies for the treatment of kidney diseases, today announced the results from the Company’s Phase 1+ clinical study of WAL0921 in healthy subjects. WAL0921 is Walden’s first-in-class, proprietary, humanized monoclonal antibody that binds circulating free soluble urokinase plasminogen activator receptor (suPAR) and its membrane bound form, uPAR, and inhibits their pathological activity, which causes kidney diseases.

Key Points: 
  • WAL0921 is Walden’s first-in-class, proprietary, humanized monoclonal antibody that binds circulating free soluble urokinase plasminogen activator receptor (suPAR) and its membrane bound form, uPAR, and inhibits their pathological activity, which causes kidney diseases.
  • The compromised kidney structure and function ultimately may lead to end-stage kidney disease requiring dialysis.
  • The Phase 1+ clinical study was a single center, placebo-controlled, single ascending dose study of WAL0921 in five cohorts that evaluated its safety, pharmacokinetics, and pharmacodynamics in 40 healthy subjects.
  • Data from the study showed that WAL0921 was safe, well-tolerated, and demonstrated proof-of-biology through a rapid, dose-dependent reduction in free suPAR levels.

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

Retrieved on: 
Mittwoch, April 10, 2024
Receptor (biochemistry), Cancer, Safety, Breast, MD, PET/CT, Patient, Neoplasm, MTIC, Therapy, Medical imaging

MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.

Key Points: 
  • MTIC will use one of the world's most sensitive, state-of-the-art, clinical total-body PET/CT (positron emission tomography–computed tomography) scanners, the Siemens Biograph Vision Quadra, to image the tumor targeting ability of MNPR-101-Zr in advanced cancer patients.
  • The Phase 1 dosimetry trial is evaluating the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancer.
  • “The Monopar team is quite excited about this trial initiation,” said Chandler Robinson, MD, Monopar’s Chief Executive Officer.
  • We are very much looking forward to seeing the biodistribution and dosimetry data from this first-in-human study in advanced cancer patients.”
    Further information about the MNPR-101-Zr trial is available at www.ClinicalTrials.gov under study identifier NCT06337084.

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
Donnerstag, März 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

Retrieved on: 
Dienstag, März 19, 2024
Receptor (biochemistry), Therapy

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.

Key Points: 
  • JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential.
  • The Company will also publish its financial and operating results for the fourth quarter and full year 2023 on March 21, 2024, in advance of the call.
  • To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call.
  • A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Donnerstag, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.

Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Donnerstag, April 4, 2024
Research, Glioblastoma, Patient, GBM, Tumor microenvironment, University, Spacecraft, Abstract (summary), Biology, Mesothelioma, AACR, PDX, Cancer, University of Copenhagen, Poster, Finsen Laboratory, GIST, ADC, Invasion, Receptor (biochemistry), Associate professor

The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.

Key Points: 
  • The data has been evaluated in collaboration with the Finsen Laboratory, Rigshospitalet/BRIC, University of Copenhagen, Copenhagen, Denmark.
  • uPARAP is a novel ADC target overexpressed by mesenchymal cancer cells including soft tissue and bone sarcomas, GIST as well as mesothelioma and glioblastoma, and has the potential to play a key role in modulating the tumor microenvironment.
  • The data demonstrate that uPARAP is strongly over-expressed in glioblastoma cells and that a uPARAP targeting ADC exhibits strong in vivo anti-tumor activity in a glioblastoma PDX model.
  • We are extremely encouraged by the data highlighted in this study, which provides further evidence on the potential effectiveness of uPARAP as a novel target for ADCs in glioblastoma multiforme.